使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Ladies and gentlemen, thank you for joining us, and welcome to the Q2 2026 Agilent Technologies Inc. earnings conference call. (Operator Instructions)
各位女士、先生,感謝各位加入,歡迎參加安捷倫科技公司(Agilent Technologies Inc.)2026 年第二季(Q2)財報電話會議。(接線員指示)
I will now hand the conference over to Tejas Savant, Vice President of Investor Relations. You may begin.
現在我將把會議交給投資人關係副總裁 Tejas Savant。您可以開始了。
Tejas Savant - Vice President of Investor Relations
Tejas Savant - Vice President of Investor Relations
Thank you, Karina, and welcome, everyone, to Agilent's conference call for the second quarter of fiscal year 2026. With me on the line are CEO, Padraig McDonnell; and CFO, Adam Elinoff. Joining for the Q&A will be Simon May, President of the Life Sciences and Diagnostics Markets Group; Angelica Reimann, President of the Agilent CrossLab Group; and Mike Zhang, President of the Applied Markets Group.
謝謝你,Karina,也歡迎各位參加安捷倫 2026 會計年度第二季的電話會議。與我同線的有執行長 Padraig McDonnell,以及財務長 Adam Elinoff。問答環節將由生命科學與診斷市場事業群總裁 Simon May、Agilent CrossLab 事業群總裁 Angelica Reimann,以及應用市場事業群總裁 Mike Zhang 一同參與。
This presentation is being webcast live. The press release for our second-quarter financial results, investor presentation and information to supplement today's discussion, along with a recording of this webcast, are available on our website at investor.agilent.com.
本次簡報將進行線上即時網路直播。我們第二季財務結果的新聞稿、投資人簡報與補充今日討論的相關資訊,以及本次網路直播的錄影,均可於我們網站 investor.agilent.com 取得。
Today's comments will refer to non-GAAP financial measures. Non-GAAP measures are supplemental and should not be considered a substitute for GAAP results. You'll find the most directly comparable GAAP financial metrics and reconciliations in the press release and on our website.
今天的發言將提及非 GAAP 財務衡量指標。非 GAAP 指標僅為補充資訊,不應視為 GAAP 結果的替代。您可在新聞稿與我們網站上找到最直接可比的 GAAP 財務指標及調節表。
Unless otherwise noted, all references to increases or decreases in financial metrics are year over year and references to revenue growth are on a core or organic constant currency basis. All references to profitability metrics are on a non-GAAP basis. Core or organic constant currency revenue growth is adjusted for the impact of currency exchange rates and any acquisitions and divestitures completed within the past 12 months. Guidance is based on forecasted exchange rates.
除非另有說明,所有財務指標的增減均為年對年比較;營收成長的提及則以核心(core)或有機(organic)的固定匯率基礎計算。所有獲利能力指標的提及均以非 GAAP 基礎計算。核心或有機固定匯率營收成長已排除匯率變動影響,以及過去 12 個月內完成之併購與處分的影響。財測指引係以預估匯率為基礎。
During this call, we will make forward-looking statements about the financial performance of the company. These statements are subject to risks and uncertainties and are only valid as of today. Agilent assumes no obligation to update them. Please refer to the company's recent SEC filings for a more detailed description of the risks and other factors that could cause our performance to differ from these forward-looking statements.
在本次電話會議中,我們將就公司財務表現發表前瞻性陳述。這些陳述受風險與不確定性影響,且僅於今日有效。安捷倫不承擔更新之義務。請參閱公司近期向 SEC 提交的文件,以取得更詳細的風險說明及其他可能導致我們表現與這些前瞻性陳述不同的因素。
And now I'd like to turn the call over to Padraig.
接下來我想把電話交給 Padraig。
Padraig McDonnell - Chief Executive Officer, Director
Padraig McDonnell - Chief Executive Officer, Director
Thanks, Tejas, and welcome, everyone. We delivered an excellent second quarter with stronger-than-expected revenue growth, significant margin expansion and double-digit EPS growth. Importantly, the quarter demonstrates that the operational and P&L benefits from our Ignite operating system are increasingly becoming structurally embedded in the business.
謝謝你,Tejas,也歡迎各位。我們交出非常出色的第二季成績:營收成長優於預期、毛利/利潤率顯著擴張,且 EPS 兩位數成長。更重要的是,本季顯示我們 Ignite 營運系統所帶來的營運與損益表(P&L)效益,正日益以結構性方式嵌入業務之中。
For the second quarter, Agilent reported $1.83 billion in revenue, growing 6.3% on a core basis and exceeding the high end of our guidance by 80 basis points. The strength was broad-based across our largest end markets and supported by continued replacement cycle momentum, innovation-led share gains and improving operational execution.
第二季,安捷倫營收為 18.3 億美元,以核心基礎成長 6.3%,並較我們指引上緣高出 80 個基點。此一強勁表現廣泛來自我們最大終端市場的支撐,並受惠於持續的汰換週期動能、以創新帶動的市占提升,以及營運執行力的改善。
Operating margin of 26.4% for the quarter represents a year-over-year improvement of 130 basis points and 180 basis points on a sequential basis, well above our guidance despite the macro and geopolitical environment. Earnings per share of $1.49 represents 14% year-over-year growth, which also exceeded the top end of our guidance by $0.07.
本季營業利益率為 26.4%,年對年提升 130 個基點,季對季提升 180 個基點;即使在總體與地緣政治環境下,仍明顯優於我們的指引。每股盈餘(EPS)為 1.49 美元,年對年成長 14%,亦較指引上緣高出 0.07 美元。
We delivered at or above our long-term plan on all metrics: revenue growth, margin expansion and EPS growth. As we enter the second half, I want to highlight the key dimensions of our strategy that are driving our performance.
我們在所有指標上都達到或超越長期計畫:營收成長、利潤率擴張與 EPS 成長。進入下半年之際,我想強調推動我們表現的策略關鍵面向。
First, we continue to build on the extraordinary level of customer intimacy and trust that we have worked hard to gain and differentiates us from the competition. This differentiation is increasingly translating into share gains across the key workflows and geographies.
第一,我們持續建立並深化與客戶之間非凡的緊密關係與信任;這是我們長期努力取得、且能讓我們有別於競爭對手的差異化優勢。這項差異化正日益轉化為在關鍵工作流程與各地區的市占提升。
Second, that trust translates into insights that inform our innovation flywheel leading to products and services that drive success for our customers and Agilent. That includes the exciting launches coming up next week at the 74th American Society for Mass Spectrometry Annual Conference in San Diego.
第二,這份信任帶來的洞察,反過來驅動我們的創新飛輪,推出能為客戶與安捷倫帶來成功的產品與服務。其中包括我們下週將在聖地牙哥舉行的第 74 屆美國質譜學會(ASMS)年會上推出的令人振奮的新產品。
Next, we have increased capabilities and the level of talent throughout the organization, improving speed, agility and operational discipline. This is driving a step function improvement in execution.
接著,我們提升了全組織的能力與人才水準,改善速度、敏捷度與營運紀律,進而帶動執行力的躍升式提升。
And finally, the significant benefits of Ignite are increasingly plain to see.. These include strategic pricing that is aiding our top-line momentum, productivity initiatives such as simplifying our structure, and generating greater value through strategic relationship management. A centralized focus on project outcomes that drives business results and increasing supply chain agility and operational discipline that is strengthening margins and business resiliency while providing flexibility to fund our most critical innovation efforts.
最後,Ignite 所帶來的顯著效益也愈發清晰可見。這些效益包括:有助於營收動能的策略性定價;例如簡化組織架構等生產力提升措施;以及透過策略性關係管理創造更高價值。以專案成果為核心的集中化管理,推動業務結果;同時提升供應鏈敏捷度與營運紀律,強化利潤率與業務韌性,並提供彈性以資助我們最關鍵的創新投入。
With our diversified and geographically balanced portfolio and healthy momentum across key end markets, the strong foundation we have built through Ignite provides us with the resiliency to compound our success and deliver results in any environment. Importantly, we expect these operational improvements to increasingly support higher quality and durable earnings growth.
憑藉我們多元且地理分布均衡的產品組合,以及在關鍵終端市場的良好動能,透過 Ignite 所建立的堅實基礎,讓我們在任何環境下都具備持續累積成功並交付成果的韌性。更重要的是,我們預期這些營運改善將日益支撐更高品質且更具持久性的獲利成長。
Before getting into the specifics of our second-quarter results, I want to spend time on the key growth drivers going forward. These include superior commercial execution combined with improvements we are seeing across our end markets, the instrument replacement cycle, our exciting slate of launches at ASMS, and our recent agreement to acquire Biocare, and how Ignite is fueling Agilent's performance.
在深入第二季結果細節之前,我想先談談未來的關鍵成長驅動因素。這些因素包括:卓越的商業執行力,結合我們在終端市場所看到的改善;儀器汰換週期;我們在 ASMS 的一系列令人期待的新品發表;以及我們近期收購 Biocare 的協議,並說明 Ignite 如何為安捷倫的表現提供動能。
We are seeing continued health in our key end markets, aligned with our expectations at the start of the year, combined with commercial execution, our differentiated portfolio and best-in-class service that helps us driving our results.
我們看到關鍵終端市場持續健康,與年初的預期一致;再加上商業執行力、差異化的產品組合與業界領先的服務,這些都在幫助我們推動業績表現。
Pharma continues to deliver with 6% growth in the quarter. This includes another quarter of low double-digit growth in biotech led by large caps, while positive demand signals from small to mid caps begin to emerge. Chemical and Advanced Materials grew a robust 8%. It was fueled by strong semiconductor demand and healthy chemical CapEx investments in the Americas. Diagnostics and Clinical grew 11%, driven by the strong performance of expanding cancer and diagnostics offerings.
製藥(Pharma)本季持續交出佳績,成長 6%。其中,生技(biotech)在大型客戶帶動下,連續一季維持低兩位數成長,同時也開始看到中小型客戶的正向需求訊號浮現。化學與先進材料成長強勁,達 8%,主要受惠於半導體需求強勁,以及美洲地區健康的化學資本支出(CapEx)投資。診斷與臨床成長 11%,由擴展中的癌症與診斷產品組合的強勁表現所帶動。
And finally, our unique technology is helping us win outside shares of forensics, where we delivered greater than 50% growth in the quarter. That includes the TSA security contract we mentioned during the last call, as well as multiple competitive large tender wins in Asia and Europe. Regarding the TSA contract, we are delighted to be able to share more details as you might have seen in our recent press release.
最後,我們獨特的技術也協助我們在法醫(forensics)領域取得外部市占,本季成長超過 50%。其中包括我們在上次電話會議提到的 TSA 安檢合約,以及在亞洲與歐洲多項大型標案中擊敗競爭對手的得標。關於 TSA 合約,我們很高興能分享更多細節,正如各位可能已在我們近期新聞稿中看到的。
The TSA would deploy our new bulk alarm resolution technology at airport security checkpoints at the FIFA World Cup host cities in the US. This unique technology provides the ability to screen larger quantities of liquids, powders and solids. With the implementation going very well, we are excited about the opportunities to apply this technology more broadly.
TSA 將在美國 FIFA 世界盃主辦城市的機場安檢通道部署我們新的大量警報判讀(bulk alarm resolution)技術。這項獨特技術可篩檢更大量的液體、粉末與固體。隨著導入進展非常順利,我們也對將此技術更廣泛應用的機會感到振奮。
We also had another very strong quarter of instrument revenue, resulting in high single-digit growth. This included market-leading low double-digit growth in LC and LC/MS and in GC. Our replacement cycle momentum continued. That, plus share gains driven by the customer-centric innovation that is embedded in our new Infinity III LC and our 8850 GC are delivering exceptional growth as customers are looking to upgrade their fleets to see how new instruments solve their most challenging workflow problems while improving efficiencies.
我們的儀器營收本季同樣非常強勁,帶動高個位數成長。其中包括在 LC 與 LC/MS,以及 GC 方面的市場領先、低兩位數成長。我們的汰換週期動能持續。再加上以客戶為中心的創新所帶動的市占提升——這些創新已融入我們全新的 Infinity III LC 與 8850 GC——正帶來卓越成長,因為客戶希望升級其設備機隊,藉由新儀器解決最具挑戰性的工作流程問題,同時提升效率。
Looking ahead, we see continued instrument strength. Our commercial excellence delivered a book-to-bill above 1 again this quarter, marking the ninth consecutive quarter where instrument orders met or exceeded revenue. Even as recent launches like the Infinity III LC at Omnis family continue to drive growth.
展望未來,我們預期儀器業務將持續強勁。我們的商業卓越表現使本季訂單出貨比(book-to-bill)再次高於 1,這是連續第九季儀器訂單達到或超過營收。即便如此,近期推出的 Infinity III LC 與 Omnis 系列仍持續帶動成長。
We are looking forward to our next wave of innovations that will further support our durable growth, strengthen our installed base and support recurring consumables and services pull through. We will showcase these new launches at ASMS next week.
我們期待下一波創新,將進一步支撐我們具持久性的成長、強化裝機基礎(installed base),並帶動耗材與服務的經常性拉動效應(pull-through)。我們將在下週的 ASMS 展示這些新產品發表。
Iâll start in spectroscopy with a revolutionary new 9500 triple quad ICP-MS, this launch brings advanced triple quad capabilities to a broader customer base by directly addressing key customer pain points around throughput, workflow complexity and operating costs. The 9500 solves these challenges with a patented Dual-Cell system that provides increased throughput and a revolutionary air mode that eliminates the need for dedicated oxygen gas, lowering operating costs and intelligent OpenLab ICP-MS software that reduces complexity and automates method migration, lowering the technical expertise required to operate the system.
我將先從光譜分析(spectroscopy)開始,推出革命性的全新 9500 三重四極桿 ICP-MS。此一發表透過直接解決客戶在產能(throughput)、工作流程複雜度與營運成本方面的關鍵痛點,將先進的三重四極桿能力帶給更廣泛的客戶群。9500 以具專利的 Dual-Cell 雙腔室系統提升產能,並具備革命性的 air mode 空氣模式,免除使用專用氧氣的需求、降低營運成本;同時搭配智慧型 OpenLab ICP-MS 軟體,降低複雜度並自動化方法移轉(method migration),降低操作系統所需的技術專業門檻。
This versatile instrument will be relevant across our customer base in advanced materials, mining, food and environmental labs. Importantly, the innovations embedded in the 9500 were a direct result of customer feedback about their most pressing problems and will serve as a differentiated architecture for ICP-MS growth well into the future.
這款多用途儀器將適用於先進材料、採礦、食品與環境實驗室等廣泛客戶群。重要的是,9500 所內建的創新直接源自客戶對其最迫切問題的回饋,並將作為 ICP-MS 未來長期成長的差異化架構。
Moving to our Gas Phase business, we are launching the upgraded flagship GCs. These launches further strengthen our position in high productivity analytical workflows where our customers increasingly prioritize efficiency automation and total cost of ownership.
接著談到我們的氣相(Gas Phase)業務,我們正在推出升級版旗艦氣相層析儀(GC)。這些新品上市進一步鞏固我們在高生產力分析工作流程中的地位,因為客戶日益重視效率、自動化以及總持有成本(TCO)。
Highlights of our new GCs include improved performance with up to 30% faster oven cooldown and higher throughput, built-in intelligence features to monitor performance track parameters and assist the proactive maintenance and the technology to conserve or eliminate helium gas with real-time gas and power usage tracking. We have been a long-standing leader in providing helium alternatives for GCs in response to customer needs. In the current helium supply environment, these productivity and resource efficiency benefits are becoming increasingly valuable for our customers.
我們新款 GC 的亮點包括:效能提升(烘箱降溫速度最高可加快 30%)與更高的處理量;內建智慧功能可監測效能、追蹤參數並協助主動維護;以及可節省或免用氦氣的技術,並可即時追蹤氣體與電力使用量。我們長期以來一直是提供 GC 氦氣替代方案的領導者,以回應客戶需求。在目前的氦氣供應環境下,這些生產力與資源效率優勢對客戶而言愈發重要。
Turning to our consumables portfolio. Altura Ultra-Inert LC columns continue to see strong traction. They grew more than 50% sequentially, reaching 75% of the top 20 biopharma accounts. This rapid adoption reinforced to strengthen innovation engine and unified commercial organization. We will continue to build on that strong initial momentum with additional waves of column launches.
接著談到我們的耗材產品組合。Altura Ultra-Inert 液相層析(LC)管柱持續展現強勁動能,較前一季成長超過 50%,並已觸及前 20 大生物製藥客戶中的 75%。這種快速採用再次印證我們強化創新引擎與整合商業組織的成效。我們將在此強勁的初期動能上持續加碼,推出更多波次的管柱新品。
Our newest Altura columns debuting at ASMS are targeted to address workflows for protein and peptide therapeutics, large oligos, gene therapy and vaccines.
我們在 ASMS 首次亮相的最新 Altura 管柱,鎖定蛋白質與胜肽治療、大型寡核苷酸(oligos)、基因治療與疫苗等工作流程需求。
On the software front, we're also expanding our capabilities in OpenLab CDS with Version 3.0. This important release provides the unified platform to support analysis for chromatography, mass spec and spectroscopy systems across our portfolio- including, for the first time, our high-resolution mass spec. The continued expansion of OpenLab order strength is workflow integration across our portfolio and enhances the strategic value of our installed base.
在軟體方面,我們也透過 OpenLab CDS 3.0 版擴充能力。這項重要版本提供統一平台,可支援我們產品組合中層析、質譜與光譜系統的分析——並且首次納入我們的高解析度質譜。OpenLab 訂單力道的持續擴張,正推動我們跨產品組合的工作流程整合,並提升我們既有裝機基礎的策略價值。
We're also delighted to announce that we are building upon our long history in China with the launch of our China innovation center. Leveraging the country's deep base of technical talent and a vibrant innovation ecosystem, we intend to strengthen our R&D capabilities across multiple emerging areas, including digital, AI and automation to better support our customers. We are particularly excited about automation, where we see excellent potential to build on our in-house capabilities with unique automation development expertise in China.
我們也很高興宣布,將在中國長期深耕的基礎上,成立並啟動中國創新中心。藉助中國深厚的技術人才庫與充滿活力的創新生態系,我們計畫在多個新興領域強化研發能力,包括數位化、AI 與自動化,以更好地支援客戶。我們對自動化尤其感到振奮,因為我們看見在中國獨特的自動化開發專長加持下,能在既有內部能力上進一步拓展的巨大潛力。
Turning to the four pillar of our strategy, I want to provide an update on the impact of our Ignite operating system that is building enterprise capabilities and driving a culture of accountability and execution excellence.
回到我們策略的四大支柱,我想更新一下 Ignite 營運系統的影響。Ignite 正在建立企業級能力,並推動問責文化與卓越執行力。
Ignite had a significant impact on the business on both the top and bottom lines during the quarter and is poised to deliver compounding benefits in the years to come. Our strategic pricing capability delivered approximately 200 basis points of pricing in Q2, putting us on a path to exceed our initial full-year goal of 100 basis points.
Ignite 在本季對營收端與獲利端都帶來顯著影響,並有望在未來數年帶來複利式效益。我們的策略性定價能力在第二季帶來約 200 個基點的價格貢獻,使我們有望超越原先全年 100 個基點的目標。
We also reached an important milestone during Q2 with the tariff task force achieving full mitigation of the incremental tariffs that began in late spring. The combination of strategic manufacturing moves and targeted price adjustments have now fully offset the operating profit impact of these tariffs. This taskforce also helped us build a playbook for addressing trade and geopolitical challenges, which has been a critical resource in navigating the current Middle East conflict.
我們在第二季也達成一項重要里程碑:關稅專案小組已完全抵消自晚春開始增加的關稅影響。透過策略性的製造布局調整與精準的價格調整組合,我們已全面對沖這些關稅對營業利益的衝擊。該小組也協助我們建立一套因應貿易與地緣政治挑戰的作戰手冊,這在我們應對當前中東衝突時成為關鍵資源。
Our digital initiative is driving accelerated growth of our e-commerce platform delivering ease of use for customers and lower cost per transaction for agent. In Q2, new digital orders grew 9%, including more than 20% ex-China. Ignite has transformed our supply chain capabilities, making it a competitive advantage.
我們的數位化計畫正推動電商平台加速成長,為客戶帶來更佳易用性,並降低代理端的單筆交易成本。第二季,新的數位訂單成長 9%,其中中國以外地區成長超過 20%。Ignite 已改造我們的供應鏈能力,使其成為競爭優勢。
A recent example of this is our quick response to the logistic challenges and material shortages arising out of the conflict in the Middle East. Ignite is providing incremental procurement savings and supply chain resilience that gives us confidence as we work to absorb inflationary cost pressures during the remainder of the year.
近期一個例子是:我們快速回應中東衝突所引發的物流挑戰與物料短缺。Ignite 正帶來額外的採購節省與供應鏈韌性,讓我們在今年剩餘期間吸收通膨成本壓力時更具信心。
On the M&A front, we were excited to announce the Biocare acquisition in March. I am confident that the robust long-term growth, strong strategic fit and opportunities for synergy realization make the financial returns on this transaction highly attractive. Ignite is driving our pre-closed preparations for the Biocare integration, ensuring we are ready to hit the ground running as soon as the transaction closes. I look forward to welcoming our new colleagues to Agilent later this year.
在併購(M&A)方面,我們很高興於三月宣布收購 Biocare。我有信心,該交易具備強勁的長期成長性、明確的策略契合度,以及實現協同效益的機會,使其財務報酬極具吸引力。Ignite 正推動我們在交易完成前的整合準備,確保交易一旦完成即可迅速展開整合。我期待在今年稍晚歡迎新同仁加入安捷倫(Agilent)。
While it's been tremendously satisfying to see Ignite's impact to date, there's a lot more to come. This includes our push for manufacturing excellence, where we are being front-footed in building resilience across our business and setting up the organization to deliver durable long-term growth. We built our AI-enabled supply chain control tower to create greater prediction and adaptive calibration of our supply and demand plans, leading to inherent resiliency, faster issue response times and much higher scheduled attainment.
雖然看到 Ignite 迄今的影響令人非常滿意,但後續還有更多成果值得期待。其中包括我們推動製造卓越的努力:我們以前瞻方式在整體業務中建立韌性,並讓組織具備交付長期、可持續成長的能力。我們建置了 AI 賦能的供應鏈控制塔,以提升對供需計畫的預測能力與自適應校準,進而形成內建韌性、更快的問題回應速度,以及更高的排程達成率。
After implementing this new capability, we have seen continued meaningful improvement in scheduled plan attainment, order conversion ratios and overall cycle times. We have also reconfigured our operations organization to a greater depth in planning, lean manufacturing and digital engineering. All of this contributes to improved delivery, greater agility and optimize cost structure. That, in turn, reduced manufacturing overhead by more than 50 basis points versus last year.
導入這項新能力後,我們看到排程計畫達成率、訂單轉換率與整體週期時間持續且顯著改善。我們也重新配置營運組織,在規劃、精實製造與數位工程方面加深能力。這些舉措共同帶來更佳交付、更高敏捷性並優化成本結構,進而使製造間接費用相較去年降低超過 50 個基點。
The 9500 ICP-MS we are featuring at ASMS is a great demonstration of how our Ignite operating system is accelerating our innovation expediting the launch by a full quarter. Our optimized approach to innovation enabled faster decisions and more focused capital allocation. We clearly established the 9500 as the top priority and dynamically reallocated resources to accelerate timelines and outcomes.
我們在 ASMS 展示的 9500 ICP-MS,是 Ignite 營運系統如何加速創新的絕佳示範,將上市時程整整提前了一個季度。我們優化後的創新方法,使決策更快、資本配置更聚焦。我們清楚將 9500 設為最高優先事項,並動態重新配置資源,以加速時程與成果。
We reinforced this through focused discipline, cross-functional execution across sales, R&D and manufacturing teams. The teams work closely to accelerate technology transfer and improve yields pulling our production readiness forward.
我們也透過聚焦的紀律與跨職能執行來強化這點,涵蓋銷售、研發與製造團隊。各團隊緊密合作,加速技術移轉並提升良率,將量產就緒時點提前。
Last but not least, AI is a key FY26 enterprise focus area for us. AI has the potential to be a tremendous growth driver for the life sciences industry. Pharma customers are leaning into AI to accelerate drug development and reduce the odds of expensive late-stage failures. There is a growing need for a large-scale multimodal data sets to train AI models, which will require significant investments in the wet lab.
最後但同樣重要的是,AI 是我們 FY26 的企業級重點領域。AI 有潛力成為生命科學產業極重要的成長驅動力。製藥客戶正積極導入 AI,以加速藥物開發並降低昂貴的後期失敗機率。市場對用於訓練 AI 模型的大規模多模態資料集需求日益增加,這將需要在濕實驗室(wet lab)進行可觀投資。
By moving the needle on drug development ROI, AI holds the promise of putting our largest customer constituency on a better footing. And a higher number of approvals coming through the drug pipeline should be a strong tailwind for us, given our leading position in downstream manufacturing QA/QC workflows. In light of the regulatory and patient safety aspects of commercial scale drug manufacturing, we believe this part of the value chain will meaningfully benefit from AI use upstream.
透過提升藥物開發的投資報酬率(ROI),AI 有望讓我們最大的客戶族群處於更有利的位置。隨著藥物研發管線中獲批數量增加,鑑於我們在下游製造 QA/QC 工作流程的領先地位,這應會成為我們的強勁順風。考量商業規模藥品製造的法規與病患安全要求,我們相信價值鏈中的這一環節將能從上游導入 AI 的使用中獲得顯著助益。
Beyond being accretive to our top line in the medium term, we are also deploying AI within our own business. I look forward to sharing more details on our AI efforts very soon.
除了在中期對我們的營收帶來增益之外,我們也正在公司內部部署 AI。我期待很快與各位分享更多我們 AI 推動工作的細節。
Now let me share some additional details on our Q2 results, starting with our end markets. As I mentioned earlier, pharma grew 6% this quarter, marking the fifth consecutive quarter of growth in the mid-single-digit to low double-digit range.
接下來我將分享第二季業績的更多細節,先從終端市場談起。如我先前提到的,本季製藥(pharma)成長 6%,這是連續第五個季度維持在中個位數到低雙位數區間的成長。
Within pharma, biotech grew low double digits for the third consecutive quarter, while small molecule grew low single digits. Our GLP-1 momentum continues delivering about 20% growth year to date, with a robust contribution from the analytical lab business in the second quarter. We also remain engaged with our large pharma customers about their plans to restore operations to the US. We continue to expect initial orders at the end of our fiscal year, with revenue starting in FY27.
在製藥領域內,生技(biotech)連續第三個季度呈現低雙位數成長,而小分子(small molecule)則為低個位數成長。我們在 GLP-1 的動能持續推進,今年迄今約成長 20%,第二季分析實驗室業務貢獻強勁。我們也持續與大型製藥客戶就其將營運恢復至美國的計畫保持互動。我們仍預期在本財年末出現初始訂單,並於 FY27 開始認列營收。
CAM grew 8% and Diagnostics and Clinical grew 11%, both exceeding expectations. Environmental & Forensics delivered 13% growth compared to low single-digit guide with the upside in Forensics, as I mentioned earlier. Environmental delivered low single-digit growth against a challenging double-digit year-over-year compare.
CAM 成長 8%,診斷與臨床(Diagnostics and Clinical)成長 11%,兩者皆優於預期。環境與法醫(Environmental & Forensics)成長 13%,相較我們原先低個位數的指引更佳,其中上行主要來自法醫,如我先前所提。環境業務在面對去年同期具挑戰性的雙位數比較基期下,仍實現低個位數成長。
Food, our second smallest end market, declined 3% with softer-than-expected results in Asia due to falling delays in China and India.
食品(Food)作為我們第二小的終端市場,下滑 3%;由於中國與印度的招標延後導致亞洲表現低於預期。
Academia and Government, our smallest end market, declined 5% in line with expectations. Most importantly, our customer-centric approach is working and we continue to win against the competition in all major geographies with share expansion, again, validated by industry market share data.
學術與政府(Academia and Government)作為我們最小的終端市場,依預期下滑 5%。最重要的是,我們以客戶為中心的策略正在奏效;我們在所有主要地區持續戰勝競爭對手並擴大市占,而這也再次由產業市占資料所驗證。
Turning to updated guidance. Building on an excellent second quarter and with the outlook for end marks broadly consistent with our original expectations, we now expect core growth of 4.5% to 6% for the full year. At the midpoint, this represents an increase of 30 basis points versus our prior guide. We are also increasing our expectations on the bottom line with updated EPS guidance of $6 to $6.10 for the full year, an increase of $0.08 at the midpoint.
接著談更新後的財測指引。在第二季表現優異、且終端市場展望大致符合我們原先預期的基礎上,我們現在預期全年核心成長率為 4.5% 至 6%。以中位數計,較先前指引上調 30 個基點。我們也上調獲利端預期,更新後全年每股盈餘(EPS)指引為 6.00 至 6.10 美元,中位數上調 0.08 美元。
And with that, let me hand it over to Adam, who will provide additional details on the quarter and our financial outlook for the remainder of the year.
說到這裡,讓我把時間交給 Adam,他將就本季表現以及我們對今年剩餘期間的財務展望提供更多細節。
Adam Elinoff - Chief Financial Officer, Senior Vice President
Adam Elinoff - Chief Financial Officer, Senior Vice President
Thanks, Padraig, and good afternoon, everyone. In my comments today, I will provide additional details on revenue in the quarter as well as walk through the income statement and cover other key financial metrics. I'll then cover our updated full-year and third-quarter guidance.
謝謝你,Padraig,各位下午好。今天我的發言將補充本季營收的更多細節,並帶大家走過損益表,同時涵蓋其他關鍵財務指標。接著我會說明我們更新後的全年與第三季財測指引。
Starting with Q2. Revenue was $1.83 billion. On our core or organic constant currency basis, we posted growth of 6.3%, while reported growth was 10%. Currency had a favorable impact of 3.7% and a slightly larger tailwind than our February guidance.
先從第二季(Q2)開始。營收為 18.3 億美元。以核心(或有機、固定匯率)口徑計算,我們成長 6.3%,而按報表口徑成長 10%。匯率帶來 3.7% 的正面影響,且順風幅度略高於我們 2 月的指引。
At a business segment level, AMG revenue grew 11% in the quarter on a core basis, well ahead of expectations. Growth was again led by double-digit performance in spectroscopy. That business continues to see strong demand for its market-leading tools to support semiconductor production at the fabs and with their downstream supply chain.
以事業部門來看,AMG 本季在核心口徑下營收成長 11%,大幅優於預期。成長再次由光譜(spectroscopy)業務的雙位數表現所帶動。該業務持續受惠於強勁需求,市場領先的工具可支援晶圓廠(fabs)的半導體生產以及其下游供應鏈。
During the quarter, AMG also benefited from the TSA airport security contract that Padraig discussed earlier. LDG revenue grew 9% on a core basis, nicely ahead of expectations. Low double-digit growth in LC and LC/MS and in our cancer diagnostics business drove the upside.
本季 AMG 也受惠於 Padraig 先前提到的 TSA 機場安檢合約。LDG 在核心口徑下營收成長 9%,同樣明顯優於預期。LC 與 LC/MS 以及我們癌症診斷業務的低雙位數成長,帶動了超預期表現。
We also saw high single-digit growth from specialty CDMO which we recently rebranded as our [Advanced Therapeutics] division. We continue to expect our Advanced Therapeutics division to deliver mid-teens growth in fiscal year 2026, with our production schedule set up to deliver a pickup in growth in the second half. Notably, we recently achieved mechanical completion of our Train C build-out, positioning us well to begin revenue generation at the new facility next spring.
我們也看到專業 CDMO(委託開發與製造)業務呈現高個位數成長;該業務近期已重新品牌化為我們的[Advanced Therapeutics]事業部。我們仍預期 Advanced Therapeutics 事業部在 2026 會計年度可達到中十位數成長,且我們的生產排程已安排在下半年帶動成長加速。值得注意的是,我們近期已完成 Train C 擴建的機械完工(mechanical completion),使我們具備良好條件於明年春季開始在新廠貢獻營收。
Our Cancer Diagnostics business, including our clinical pathology products and companion diagnostic services grew low double digits this quarter. This growth was led by the performance of our new Omnis family, which continues to gain traction.
我們的癌症診斷業務(包含臨床病理產品與伴隨診斷服務)本季成長低雙位數。成長主要由我們新的 Omnis 產品家族表現帶動,該系列持續獲得市場採用並加速滲透。
We also saw strong double-digit growth in pathology reagents, driven by our expanding instrument installed base. This business is performing extremely well and will get even stronger with the addition of Biocare's clinically focused antibody menu.
我們也看到病理試劑(pathology reagents)強勁的雙位數成長,主要受惠於我們儀器裝機量(installed base)的擴大。該業務表現極為出色,並將因新增 Biocare 以臨床為導向的抗體產品組合(antibody menu)而進一步增強。
ACG grew 2% in the quarter on a core basis, in line with guidance. Due to Lunar New Year timing and a challenging consumables compared driven by pre-tariff stocking in China last year. Ex-China, ACG grew at the high end of mid-single digits and consumables grew high single digits.
ACG 本季在核心口徑下成長 2%,符合指引。主要受到農曆新年時點影響,以及耗材(consumables)比較基期偏具挑戰(去年中國因關稅前備貨而墊高基期)。在中國以外地區,ACG 成長達到中個位數區間的高端,而耗材成長為高個位數。
On a geographic basis, we saw our strongest results in the Americas with 11% revenue growth. We saw broad high single-digit-plus results in all end markets, except Academic and Government. Europe, and Asia, ex-China, revenue grew high single digits with excellent diagnostics momentum in Europe, while pharma and semiconductor investments were strong in Asia, ex-China.
以地區來看,美洲表現最強,營收成長 11%。除學術與政府(Academic and Government)外,各終端市場普遍呈現高個位數以上的成長。歐洲與亞洲(不含中國)營收皆成長高個位數;其中歐洲診斷業務動能極佳,而亞洲(不含中國)則受惠於製藥與半導體投資強勁。
China declined 9%. And a bit more than we had expected. On a first-half basis, China was roughly flat, very much in line with our full-year guide.
中國下滑 9%,且降幅略高於我們預期。以上半年來看,中國大致持平,與我們全年指引非常一致。
Q2 gross margins were 55%. On a year-over-year basis, gross margins increased by 90 basis points from nice leverage on incremental volumes, Ignite momentum and favorable regional mix. Operating margin was 26.4%, an increase of 130 basis points year over year, well ahead of guidance, driven by our healthy gross margin performance and continued realization of Ignite operating system efficiencies.
第二季毛利率為 55%。年對年來看,毛利率提升 90 個基點,主要來自增量出貨帶來的良好槓桿效應、Ignite 動能,以及有利的區域組合。營業利益率為 26.4%,年對年提升 130 個基點,明顯優於指引,主要由健康的毛利表現與持續落實 Ignite 營運系統效率所驅動。
Moving below the line, we had $11 million of other income, while our tax rate of 14.5% was as expected. Finally, we had 283 million diluted shares outstanding in the quarter, in line with expectations. Putting it all together, Q2 earnings per share were $1.49 and grew 14% and a reflection of our superior execution and operational excellence.
在業外項目方面,我們有 1,100 萬美元的其他收益(other income),而 14.5% 的稅率符合預期。最後,本季稀釋後流通股數為 2.83 億股,符合預期。綜合以上,第二季每股盈餘(EPS)為 1.49 美元,成長 14%,反映我們卓越的執行力與營運優勢。
Now let me turn to cash flow and the balance sheet. Operating cash flow was $277 million in the quarter and we invested $76 million in capital expenditures. Q2 cash flow reflects a tax deposit that will largely be offset by a related refund anticipated around the end of the fiscal year. We purchased $65 million in shares and paid $72 million in dividends in Q2, and we ended the quarter with a net leverage ratio of 0.7 turns, maintaining our strong balance sheet.
接著談現金流與資產負債表。本季營運現金流為 2.77 億美元,資本支出投資 7,600 萬美元。第二季現金流反映了一筆稅款存入(tax deposit),預計在會計年度末前後收到相關退稅而大致抵銷。我們在第二季回購 6,500 萬美元股票並支付 7,200 萬美元股利;季末淨槓桿比率為 0.7 倍(turns),維持強健的資產負債表。
Now let me share some additional details on the updated outlook for the year and the guidance for the third quarter.
現在我將分享更新後的全年展望,以及第三季指引的更多細節。
Based on the strong performance, we now expect fiscal year 2026 revenue to be in the range of $7.39 billion to $7.49 billion on a reported basis. This range represents growth of 4.5% to 6% on a core or organic constant currency basis, an increase of 30 basis points at the midpoint versus the prior guide. Currency is now expected to be a 1.8% tailwind during the year.
基於強勁表現,我們目前預期 2026 會計年度按報表口徑的營收將落在 73.9 億至 74.9 億美元區間。此區間代表以核心(或有機、固定匯率)口徑計算成長 4.5% 至 6%,中位數較先前指引上調 30 個基點。匯率目前預期將在全年帶來 1.8% 的順風。
Turning to our end markets, business segment and geographic growth assumptions. We continue to expect high single-digit growth in Pharma in a low single-digit decline in Academic and Government. Based on strong results in the first half and our outlook for the remainder of the year, we are raising our expectations for Chemicals and Advanced Materials as well as Diagnostics and Clinical from mid-single-digit to mid- to high single-digit growth.
接著談終端市場、事業部門與地區的成長假設。我們仍預期製藥(Pharma)維持高個位數成長,而學術與政府(Academic and Government)為低個位數下滑。基於上半年強勁結果以及對今年剩餘期間的展望,我們將化學與先進材料(Chemicals and Advanced Materials)以及診斷與臨床(Diagnostics and Clinical)的成長預期,從中個位數上調至中到高個位數。
With our momentum in forensics providing upside, we are raising our guidance for Environmental and Forensics from low single digit to low to mid-single-digit growth. In Food, we are lowering our guide from roughly flat to a low single-digit decline due to delays in government funding in China and India and inflationary headwinds related to the Middle East conflict.
鑑於法醫(forensics)動能帶來上行空間,我們將環境與法醫(Environmental and Forensics)的指引從低個位數上調至低到中個位數成長。在食品(Food)方面,由於中國與印度政府資金撥付延遲,以及中東衝突相關的通膨逆風,我們將指引從大致持平下調至低個位數下滑。
We now expect mid-single-digit growth for all three business segments, increasing AMG from low single digit to mid-single digit to reflect the strong Q2 performance. Regionally, our only update to our prior full year guidance is in Asia, ex-China, where we are increasing our assumptions from mid-single digits to mid- to high single-digit growth.
我們目前預期三大事業部門皆為中個位數成長,並將 AMG 從低個位數上調至中個位數,以反映第二季的強勁表現。就區域而言,我們對先前全年指引的唯一更新是亞洲(不含中國),我們將假設從中個位數上調至中到高個位數成長。
Moving down the P&L. We are also raising our full-year operating margin expansion target to 85 basis points at the midpoint of our revenue guidance, driven by continued operational momentum. Our expected tax rate is unchanged at 14.5%, and we now expect $31 million in other income and 283 million diluted shares outstanding for the year. Fiscal year '26 earnings per share are now expected to be between $6 and $6.10, an increase of $0.08 at the midpoint, representing earnings growth of 7% to 9%.
往下看損益表(P&L)。在持續的營運動能帶動下,我們也將全年營業利益率擴張目標上調至在營收指引中位數下擴張 85 個基點。預期稅率維持 14.5% 不變;我們目前預期全年其他收益為 3,100 萬美元,稀釋後流通股數為 2.83 億股。2026 會計年度每股盈餘目前預期介於 6.00 至 6.10 美元,中位數上調 0.08 美元,代表獲利成長 7% 至 9%。
For your modeling, let me share some additional expectations we have incorporated into our guidance for the year.
為便於各位建模,我再分享一些我們已納入全年指引的額外假設。
While the Middle East conflict in the demand for memory chips puts upward pressure on our costs, we are confident that the Ignite operating system will deliver meaningful efficiencies and help absorb those inflationary impacts within our H2 outlook. There is no change to our operating cash flow range of $1.6 billion to $1.7 billion, and we are now expecting to invest approximately $450 million in capital expenditures, down $50 million versus our prior guidance.
雖然中東衝突以及記憶體晶片需求使我們成本面臨上行壓力,但我們有信心 Ignite 營運系統將帶來顯著效率,並在下半年(H2)展望中協助吸收這些通膨影響。我們的營運現金流區間維持 16 億至 17 億美元不變;同時我們目前預期資本支出約 4.5 億美元,較先前指引下調 5,000 萬美元。
Now moving to the third quarter. We expect our reported revenue to be in the range of $1.83 billion to $1.85 billion. This represents growth of roughly 4.4% to 5.9% on a core or organic constant currency basis, while currency is expected to be approximately a 0.6% tailwind. Our guide assumes 283 million diluted shares outstanding in the third quarter.
接著談第三季。我們預期按報表口徑的營收將落在 18.3 億至 18.5 億美元區間。這代表以核心(或有機、固定匯率)口徑計算約成長 4.4% 至 5.9%,而匯率預期約帶來 0.6% 的順風。我們的指引假設第三季稀釋後流通股數為 2.83 億股。
EPS guidance for the quarter is $1.48 to $1.50, representing growth of 8% to 9%. While our second-half core growth guidance is roughly similar to our first-half performance, it comes against the backdrop of increasingly tougher comps. The sequential quarterly two-year stack growth implied by our guidance demonstrates our accelerating momentum through the year, as shown on slide 10 of our presentation.
本季 EPS 指引為 1.48 至 1.50 美元,代表成長 8% 至 9%。雖然我們對下半年核心成長的指引與上半年表現大致相近,但將面臨愈來愈具挑戰的比較基期。依據我們指引所隱含的逐季兩年疊加(two-year stack)成長,顯示我們全年動能正在加速,如簡報第 10 頁所示。
Finally, I wanted to be clear that our guide does not include the impact of Biocare nor any benefit from potential tariff refunds.
最後我想明確說明,我們的指引不包含 Biocare 的影響,也不包含任何潛在關稅退稅(tariff refunds)的利益。
With that, I'll turn the call back over to Padraig for closing comments.
說到這裡,我把電話會議交回給 Padraig 作結語。
Padraig McDonnell - Chief Executive Officer, Director
Padraig McDonnell - Chief Executive Officer, Director
Thanks, Adam. I couldn't be prouder of the way our team executed in the second quarter, once again demonstrating our ability to perform in all market environments.
謝謝你,Adam。我對我們團隊在第二季的執行表現感到無比自豪,再次展現我們在各種市場環境下都能交出成績的能力。
In the near term, our improved full-year outlook reflects healthy demand in our key end markets and stronger underlying operational performance across the business. That includes pricing realization, productivity gains and replacement cycle momentum.
短期來看,我們上調全年展望,反映出我們主要終端市場需求健康,以及全公司更強勁的基礎營運表現。其中包括價格落實、生產力提升與汰換週期動能。
Longer term, our broad and diverse portfolio across end markets and geographies provide differentiated resiliency and enables multiple avenues to success. We're a market-leading services team that cultivates unparalleled customer intimacy, a deep bench of talent, an impressive cadence of innovation launches and our Ignite operating system that has come into its own and is delivering compounding results. Agilent will continue to sustainably outperform the competition.
長期而言,我們橫跨終端市場與地理區域的廣泛且多元產品組合,提供差異化的韌性,並帶來多條成功路徑。我們擁有市場領先的服務團隊,培養無與倫比的客戶親密度、深厚的人才梯隊、令人印象深刻的創新上市節奏,以及已日臻成熟、並持續帶來複利式成果的 Ignite 營運系統。安捷倫將持續以可持續的方式超越競爭對手。
Before we close, I want to take a moment to thank our customers for their trust and express my gratitude to the Agilent team for delivering a fantastic results.
在結束之前,我想花點時間感謝客戶的信任,並向安捷倫團隊致上謝意,感謝大家交出非常出色的成果。
And with that, I'll turn the call back to Tejas for the Q&A. Tejas?
接下來,我把電話交回給 Tejas 進行問答環節。Tejas?
Tejas Savant - Vice President of Investor Relations
Tejas Savant - Vice President of Investor Relations
Thanks, Padraig. Karina, can you please share the instructions for the Q&A?
謝謝你,Padraig。Karina,麻煩你說明一下問答環節的指示。
Operator
Operator
(Operator Instructions) Vijay Kumar, Evercore.
(接線員指示)Vijay Kumar,Evercore。
Vijay Kumar - Equity Analyst
Vijay Kumar - Equity Analyst
Congrats on a fine print here. Maybe my first one on -- if you look at some of the moving pieces here, the CAM was standout for us. On the instrument side, LC/MS, GC, double digits was a standout. But it looks like overall, instruments, high singles implies your cell analysis was still down. So maybe talk about -- is that A&G? What are you seeing in A&G trends?
恭喜這次表現很不錯。我第一個問題是——如果看這裡的一些變動因素,CAM 對我們來說特別突出。在儀器端,LC/MS、GC 以雙位數成長也很亮眼。但看起來整體而言,儀器的高個位數成長意味著你們的細胞分析仍在下滑。所以想請你談談——那是 A&G 嗎?你們在 A&G 的趨勢上看到什麼?
And on the CAM side, I know with the Middle East situation, there's been some talks about end market concerns. Maybe talk about how CAM progress and your confidence in that CAM outlook.
另外在 CAM 方面,我知道隨著中東局勢,有一些關於終端市場疑慮的討論。能否談談 CAM 的進展,以及你們對 CAM 展望的信心?
Padraig McDonnell - Chief Executive Officer, Director
Padraig McDonnell - Chief Executive Officer, Director
Great. Thanks, Vijay. And first of all, we're delighted with the results, really strong results from the team where we're taking share across the board. And Ignite really running on all cylinders.
很好,謝謝你,Vijay。首先,我們對結果非常滿意,團隊交出非常強勁的成績,我們在各方面都在擴大市占。而 Ignite 也確實火力全開。
But CAM was 8% growth in Q2. That beat our mid-single-digit guide -- plus mid-single-digit guide. We're mid-single digits in Chemicals, high middle single digits and low double digits in Advanced Materials. And we had actually low teens CAM growth, ex-China. So after a strong high single-digit growth in H1, we're going to see how it plays out with the Middle East going forward on it.
不過 CAM 在第二季成長 8%,高於我們「中個位數」的指引——而且是高於中個位數指引。我們在化學領域是中個位數成長;先進材料是中到高個位數、以及低雙位數成長。若排除中國,CAM 成長其實達到低十幾%。因此,在上半年強勁的高個位數成長之後,接下來我們會觀察中東情勢對後續的影響。
And it's really driven by a number of things. I think increased CapEx spending likely returns late in the calendar year, but we're seeing that continued investment in the semiconductor space. That continues to be a real sweet spot for us. And what we're seeing is also is substantial leadership in our key platforms.
而這主要是由多項因素驅動。我認為資本支出(CapEx)增加很可能在曆年年底回升,但我們看到半導體領域的投資仍在持續,這一直是我們真正的甜蜜點。同時我們也看到,我們在關鍵平台上具備顯著的領導地位。
Now when you look ahead and you look and see what are multiple factors. I think the chemical sector driven by demand from downstream material industries like semiconductors and batteries continued investment in semiconductor and investment in supply chains. So overall, really strong across the board.
再往前看、考量多個因素,我認為化學產業是由下游材料產業(如半導體與電池)的需求所帶動,半導體投資與供應鏈投資也在持續。因此整體而言,各方面都非常強勁。
And we don't read too much into the Middle East in terms of what's happening. We're going to see how that goes. But we're seeing good momentum in our funnels continue on the CAM side.
至於中東情勢,我們不會過度解讀其影響,我們會持續觀察後續發展。但在 CAM 方面,我們看到銷售漏斗的良好動能仍在延續。
And I think, on the Academia and Government side, I think you had a question in there. We expected a decline. We have a decline of minus 5% in Q2. Americas' revenue was flat. Americas instruments comps start to ease actually, and we see return to stability on that side. And you see that the OMB requirement to fully redistribute appropriate funds is starting to happen.
另外我想你也問到了學術與政府(Academia and Government, A&G)。我們原本就預期會下滑,第二季下滑 -5%。美洲地區營收持平。美洲的儀器比較基期其實開始趨於緩和,我們也看到那一端回到穩定。同時你也看到,OMB 要求將適當資金全面重新分配的作業正開始推進。
So overall, we see it continuing as a kind of a steady state and we see ongoing kind of, I would say, ongoing muted in A&G. But overall, I think, an extremely strong result.
所以整體來看,我們認為它會維持在某種穩態;A&G 仍然偏向低迷。但總體而言,我認為這是一個極其強勁的結果。
Vijay Kumar - Equity Analyst
Vijay Kumar - Equity Analyst
That's helpful. And maybe Adam, one for you on the margins. Pretty impressive margin print here. It looks like volumes -- volumes were slightly above the high end of your guidance, but the leverage was pretty impressive. How much was pricing?
這很有幫助。接著可能想請教 Adam 一個關於毛利率的問題。這次毛利率表現相當亮眼。看起來出貨量——出貨量略高於你們指引區間的上緣,但槓桿效應非常驚人。其中有多少是來自定價?
Maybe talk about what drove margins and how you're thinking about progression here? It looks like Q4 we're looking at a pretty big quarter for margins, maybe visibility into Q4 ramp?
也請談談是什麼驅動了毛利率,以及你們如何看待後續走勢?看起來第四季的毛利率會是一個相當大的季度,能否分享一下對第四季爬坡的能見度?
Adam Elinoff - Chief Financial Officer, Senior Vice President
Adam Elinoff - Chief Financial Officer, Senior Vice President
Yeah. So thanks, Vijay. A couple of points. So the margin beat this quarter was driven by a couple of things. One, Ignite, and I say that in the broadest sense of the word, so that includes the pricing. So you heard over 200 bps of pricing in there as well as execution excellence from the team and structural improvements we're seeing -- we talked about in the script, specifically in operations as well as productivity from our procurement team. So all of the Ignite savings you're really starting to see run through the P&L now. Then there's volume leverage.
好的。謝謝你,Vijay。我補充幾點。本季毛利率優於預期主要由幾個因素帶動。第一是 Ignite——我用最廣義的定義來說,這也包含定價。因此你聽到其中有超過 200 個基點(bps)來自定價,另外還有團隊卓越的執行力,以及我們看到的結構性改善——我們在講稿中提到,特別是在營運端,以及採購團隊帶來的生產力提升。所以你現在真的開始看到所有 Ignite 節省反映在損益表(P&L)上。接著還有出貨量帶來的槓桿效應。
The other piece I would point out is the geographic mix as we had a larger skew in Q2 toward the Americas, which helps our margin.
另外一點要指出的是地理組合:第二季我們在美洲的比重更高,這有助於提升毛利率。
And then if we look ahead, what you see is two things. One, you see a flat sequential Q2 to Q3, and that's really driven by a couple of pieces. One, you see the favorability that we have in Ignite. And once again, that's the broadest sense of the Ignite operating system there. And then that's partially offset by some inflationary pressures that we're seeing and geographic mix kind of returning back to a little bit more of a normalized mix.
再往前看,你會看到兩件事。第一,第二季到第三季的序列變動大致持平,主要由幾個因素驅動:一方面是 Ignite 帶來的有利影響——同樣是以最廣義的 Ignite 營運系統來看;但另一方面,部分被我們看到的一些通膨壓力,以及地理組合回到較正常水準所抵銷。
But then what you see is the expansion happening again from Q3 to Q4, up about 220 bps, which is very normal from what we've seen in previous quarters. And when I kind of look at it and take a step back, our H1 to H2 ramp is about [4,753] from an operating profit perspective. And this is very much normalized what we would normally see H1 to H2. So the ramp here is fully in line with historical norms. So we feel very confident about it and really excited about the second half of the year.
但接著你會看到第三季到第四季毛利率再次擴張,上升約 220 個基點,這與我們過去季度看到的情況非常一致。當我退一步看,從上半年到下半年的爬坡,以營業利益角度約為 [4,753]。這非常符合我們通常在上半年到下半年會看到的正常水準。因此這次的爬坡完全符合歷史常態。我們對此非常有信心,也對下半年感到非常振奮。
Operator
Operator
Patrick Donnelly, Citi.
Patrick Donnelly,花旗(Citi)。
Patrick Donnelly - Analyst
Patrick Donnelly - Analyst
Maybe one on the specialty CDMO, I guess it's Advanced Therapeutics now. It sounds like high single-digit growth in the quarter, pretty healthy there. Obviously, talking still about the mid-teens. I think you talked about the production schedule has this uptick in 2H.
我想問一個關於專業 CDMO 的問題,我想現在稱為 Advanced Therapeutics。聽起來本季是高個位數成長,表現相當健康。你們仍在談中十幾%的成長。我記得你們提到下半年生產排程會有一個上升。
Can you just talk about the visibility? Is that all kind of contracted and covered at this point? It sounds like Train C next spring, so maybe not this year. But just talk about the visibility on the second half uptick of that business. What you saw in the quarter? How much go-forward revenue is covered by some of the contracts that you have in place here?
能否談談能見度?目前這些是否都已簽約並涵蓋了?聽起來 C 產線(Train C)要到明年春天,所以可能不是今年。但請談談該業務下半年上升的能見度:本季你們看到了什麼?未來收入有多少是由你們目前已簽訂的合約所覆蓋?
Padraig McDonnell - Chief Executive Officer, Director
Padraig McDonnell - Chief Executive Officer, Director
Yeah. Thanks, Patrick, and thanks for the question. So I'll start off and I'll hand it over to Simon for more detail.
好的,謝謝你,Patrick,也謝謝你的問題。我先做個開場,然後把更細節的部分交給 Simon。
So just to kind of ground people, we're a specialty CDMO business focus on sRNA, peptides, GLP-1s and of course, high potency APIs. And the Q2 growth at the high end of high single digits was within expectations with batch cadence resulting in a normal quarter-to-quarter variance. We see that over and over again. We continue to see -- expect to see mid-teens growth guide for FY26 based on our production schedules and demand dynamics.
先讓大家有個基礎認知:我們是一個專業 CDMO 業務,聚焦於 sRNA、胜肽、GLP-1,以及當然還有高效價 API(高活性原料藥)。第二季在高個位數成長的上緣,符合預期;由於批次節奏(batch cadence),季度之間出現正常的波動。我們一再看到這種情況。我們仍然看到——也預期——基於我們的生產排程與需求動態,FY26 全年指引為中十幾%的成長。
But at Simon -- add some more color on the Train, et cetera.
不過關於 Train 等等,請 Simon 再補充一些細節。
Simon May - Senior Vice President, President - Life Sciences and Diagnostics Markets Group
Simon May - Senior Vice President, President - Life Sciences and Diagnostics Markets Group
Yeah. Thanks., Padraig This is Simon. Just to add a little bit more color there. The short answer to the question is we've got really strong visibility in the second half of the year. And the phasing of production schedules point towards very strong year-over-year growth in the third quarter. And in the fourth quarter, we've got a tough compare in the fourth quarter, but it all adds up still to mid-teens growth for the year is what we're projecting.
好的,謝謝,Padraig。我是 Simon。我再補充一些背景。這個問題的簡短答案是:我們對下半年有非常強的能見度。生產排程的時點安排顯示第三季的年對年成長會非常強勁。第四季的比較基期較高,但加總起來,我們仍預估全年會達到中十幾%的成長。
And then as you heard already in the script, we had a major milestone here in the second quarter with the mechanical completion of Train C. Very pleasing to see that, and we remain on schedule there for go live in the spring of 2027.
另外如同你在講稿中已聽到的,我們在第二季達成一個重要里程碑:Train C 的機械完工(mechanical completion)。看到這點非常令人欣慰,我們也仍按計畫在 2027 年春季上線(go live)。
And we're a little further out there with demand into 2027, but some very encouraging signs already with Train C in particular, we've got strong line of sight to demand there for the bulk of FY27. But as is always the case to further out you get in the timing, the production schedules and the bookings, they proceed accordingly.
至於 2027 年的需求,我們目前看得更遠一些,但已經出現一些非常令人鼓舞的跡象。特別是針對 Train C,我們對 FY27 大部分期間的需求已有很強的可視性。不過一如往常,時間拉得越遠,生產排程與接單(bookings)也會隨之逐步推進與落實。
Patrick Donnelly - Analyst
Patrick Donnelly - Analyst
Okay. That's really helpful. And then, Padraig, maybe one of the instrument strengths, just following up there. Nice to see low double-digit growth in LC/LCMS. Can you just talk about what markets you're seeing that strength in?
好的。這真的很有幫助。接著,Padraig,或許就儀器的優勢再追問一下。很高興看到 LC/LCMS 以低雙位數成長。你能談談你看到這股強勢主要來自哪些市場嗎?
I know you guys have the replacement cycle going. How much of it is replacement cycle, share gains? What are you hearing from the field on the instruments? And how durable is this kind of low double digits for the LCMS program?
我知道你們正處於汰換週期。這當中有多少是汰換週期、多少是市占提升?你們從前線對儀器端聽到的是什麼?另外,LCMS 專案這種低雙位數成長的可持續性如何?
Padraig McDonnell - Chief Executive Officer, Director
Padraig McDonnell - Chief Executive Officer, Director
Yes. So look, I think we continue to see strong momentum on the LCMS and GC, low double digits for both businesses. And we expect the LC replacement cycle to be a 200, 300 bps tailwind to the LC growth. And we've seen that normal trajectory of the replacement cycle, but continued momentum and funnels look really strong.
是的。所以你看,我認為我們在 LCMS 和 GC 上持續看到強勁動能,兩個業務都是低雙位數成長。我們預期 LC 的汰換週期將為 LC 成長帶來 200 到 300 個基點(bps)的順風。我們也看到汰換週期的正常軌跡,同時動能延續、銷售漏斗看起來非常強勁。
I will say it was actually the best market share data I've seen in what we're seeing. So not only are we replacing, but we're also taking share in competitive accounts, which, again, continues the momentum. And if you kind of break it down I think it's really driven by three factors. I think underinvestment, fleets of age, you see US and Europe CapEx conditions are favorable. And of course, customer-focused innovations are compelling reasons to replace. So we expect that to continue. And we're seeing it across all markets.
我想說,這其實是我所見過最好的市占資料。不只是汰換,我們也在競爭性客戶中拿下市占,這再次延續了動能。若要拆解來看,我認為主要由三個因素驅動:投資不足、設備機隊老化;你看到美國與歐洲的資本支出(CapEx)條件有利;當然,以客戶為中心的創新也提供了很有說服力的汰換理由。因此我們預期這會持續,而且我們在所有市場都看得到。
And I really want to call out our GC replacement cycle as well. It sometimes under talked about. But on our GC, we're low double-digit growth. It's a longer-lived nature of the GC. You see a typical life span of 10 years. And we see relatively LC replacement cycle will drive more moderate annual uplift over a longer period of time, but very, very compounding. And we expect that to be 100 bps of the tailwind.
我也想特別點出我們的 GC 汰換週期,這有時候較少被提到。但在 GC 方面,我們是低雙位數成長。GC 的使用壽命更長,典型壽命約 10 年。我們看到相較於 LC,GC 的汰換週期會在更長期間帶來較溫和的年度提升,但會非常、非常具有複利效果。我們預期這將帶來 100 個基點的順風。
So instruments are really good. Funnel is really strong. The CapExs are being released and none of this will be possible without a commercial team that can really execute on these innovations.
所以儀器端表現真的很好,漏斗也非常強。資本支出正在釋放;而若沒有能夠真正把這些創新落地執行的商業團隊,這一切都不可能發生。
Operator
Operator
Tycho Peterson, Jefferies.
Tycho Peterson,Jefferies。
Tycho Peterson - Analyst
Tycho Peterson - Analyst
Padraig, I want to provide a little more on the semi strength. This is something you haven't talked a ton about, but maybe just quantify the size of the semi business today. I think you're more levered to logic been memory, if that's right.
Padraig,我想再多談一點半導體(semi)的強勁表現。這是你們較少深入談的部分,但能否量化一下目前半導體業務的規模?我想你們的曝險比較偏向邏輯(logic)而非記憶體(memory),如果我理解正確的話。
But just talk a little bit about sustainability of double-digit growth in spectroscopy, how we should think about new fab construction and pricing power. I think there seems to be a fair amount of pricing power in this market right now.
另外也請談談光譜(spectroscopy)雙位數成長的可持續性,我們應該如何看待新晶圓廠(fab)建設與定價能力。我覺得目前這個市場似乎有相當程度的定價能力。
Padraig McDonnell - Chief Executive Officer, Director
Padraig McDonnell - Chief Executive Officer, Director
Yeah. I mean there's a really strong pricing power. And of course, we have a new system being released at ASMS that's going to start its own replacement cycle in this area, which is driven by the technology with new capabilities.
是的。我的意思是,定價能力確實非常強。當然,我們在 ASMS 會發布一套新系統,這將在這個領域啟動它自己的汰換週期,主要由具備新能力的技術所驅動。
Our Advanced Materials market, if you split it out on the Chemical and Advanced Materials, semiconductor is about 30% of that market as we look at it. And we're seeing continued growth on it. And we're seeing it in the fabs, but also in the high-purity chemical companies around fabs that need these systems as well to do it.
我們的先進材料(Advanced Materials)市場,如果把 Chemical 和 Advanced Materials 拆開來看,半導體約占我們所定義的該市場的 30%。我們看到它持續成長;我們在晶圓廠端看到,也在晶圓廠周邊的高純化學品公司看到,這些公司同樣需要這些系統來完成相關作業。
So we're seeing it across the board. We've actually saw that over a number of years, Tycho, you see CapEx being deployed. Our systems are being placed inside and then, of course, are qualified with the fabs going forward. So as that cycle continues to move, you're going to see that business continue to grow on it. So we're very optimistic.
所以我們是全面都看得到。Tycho,我們其實在過去好幾年就看到資本支出在部署;我們的系統被放進廠內,接著當然會在後續與晶圓廠一起完成認證(qualified)。因此,隨著這個循環持續推進,你會看到這塊業務持續成長。我們非常樂觀。
Tycho Peterson - Analyst
Tycho Peterson - Analyst
And then on Chemical, you did kind of buck the trend here. I know Vijay kind of asked the question earlier. But are you kind of not seeing what others are on the Chemical side because of the GC replacement cycle? Is that kind of the right way to think about it?
那在 Chemical 方面,你們確實有點逆勢而行。我知道 Vijay 先前也問過這個問題。但你們在 Chemical 端沒有看到其他人看到的情況,是不是因為 GC 汰換週期的關係?這樣理解對嗎?
Padraig McDonnell - Chief Executive Officer, Director
Padraig McDonnell - Chief Executive Officer, Director
Yeah. I think it's a mixture of both. I think we've seen strong CapEx demand. The GC replacement cycle is certainly a tailwind we're seeing. We're -- and very, very competitive with the new innovations that we bring across.
是的。我認為兩者都有。我們看到強勁的資本支出需求;GC 汰換週期確實是我們看到的一股順風。我們——而且我們在所推出的新創新上也非常、非常有競爭力。
But we haven't seen a slowdown in that area. People are still -- have aging fleets to need them replaced and so on. And of course, it's kind of a bifurcation. So chemical sector is driven downstream on the materials on semiconductors batteries and advanced polymers. And of course, we continue to see that continue under replacement momentum after several years of underinvestment in CapEx. So we don't see that stopping anytime soon.
但我們沒有在那個領域看到放緩。大家仍然——設備機隊老化,需要汰換等等。當然,這有點分化(bifurcation)。化學產業的需求在下游主要由半導體、電池與先進聚合物等材料所驅動。而且在資本支出多年投資不足之後,我們持續看到汰換動能延續。因此我們不認為這會在短期內停止。
Operator
Operator
Puneet Souda, Leerink.
Puneet Souda,Leerink。
Puneet Souda - Analyst
Puneet Souda - Analyst
First one. Just given the -- if I could continue to follow up on the semi side and the CAM side. Can you elaborate how CAM improved throughout the quarter? Your confidence here, is this more semi-driven or instrumentation versus the overall improvement in Chemical?
第一個問題。就——如果我可以繼續追問半導體端與 CAM 端。你能否說明 CAM 在整個季度是如何改善的?你在這裡的信心來源,是更多由半導體驅動,還是由儀器端驅動,抑或是 Chemical 整體改善所帶動?
Obviously, there was a -- I mean, the start of the conflict, but then the conflict has eased a bit. Maybe just talk about how the trend line has been and what gives you will continue more confidence in that core oil and gas business as well?
顯然,當時——我是說,衝突一開始,但之後衝突似乎稍微緩和了一些。也請談談趨勢線的變化,以及是什麼讓你對核心油氣(oil and gas)業務也能持續更有信心?
Padraig McDonnell - Chief Executive Officer, Director
Padraig McDonnell - Chief Executive Officer, Director
Yeah. Look, our momentum has been really, really steady and increasing. And we are very, very pleased with the high single digits in Q2. And if you think about it, our differentiation in terms of the technologies are driving share gains in Advanced Materials, where we saw low double-digit growth. And of course, inflationary pressures from the Middle East may affect capital spend but we expect a strong recovery to be even accelerated before that, but we're not seeing that in our numbers.
是的。你看,我們的動能一直非常、非常穩定且在提升。我們對第二季(Q2)高個位數成長感到非常、非常滿意。若你這樣想,我們在技術上的差異化正推動先進材料的市占提升,我們在那裡看到低雙位數成長。當然,中東的通膨壓力可能影響資本支出,但我們原本預期強勁復甦會在那之前甚至加速,不過我們在數字上並沒有看到這種影響。
And just to kind of ground people, we're number one in the CAM market by far. We have substantial leadership positions in GC and GCMS and spectroscopy, and we're pleased with the really strong performance.
再補充一下背景,我們在 CAM 市場遠遠是第一名。我們在 GC、GCMS 與光譜領域都有顯著的領導地位,我們也對非常強勁的表現感到滿意。
Now, CAM customers tend to be more cautious in a dynamic macro environment. So we're watching closely on the inflationary pressures that may have on our customers. But I would say, overall, if you pull it together, there's a degree of prudence embedded in our H2 outlook. We growth accelerating from high single digits to mid-single digits in H2, but still very robust.
不過,CAM 客戶在多變的總體環境下往往更為謹慎。因此我們正密切關注通膨壓力可能對客戶造成的影響。但我會說,整體而言,如果把它綜合起來,我們的下半年(H2)展望中已內含一定程度的審慎。我們的成長在下半年會從高個位數放緩到中個位數,但仍然非常穩健。
Puneet Souda - Analyst
Puneet Souda - Analyst
Got it. And then a broader question for you. On the Agilent differentiation, you're clearly outperforming versus rest of the broader tools market, the diversified market diversification beyond health care seems to be helping you. But could you take a minute and provide a view into the pharma and the biotech business, how are you serving those customers from discovery versus more preclinical?
了解。接著一個更廣泛的問題。就安捷倫(Agilent)的差異化而言,你們明顯優於其他更廣泛的工具市場;在醫療保健以外的多元化似乎也在幫助你們。但你能否花一點時間談談製藥與生技業務:你們如何從藥物發現(discovery)到更偏臨床前(preclinical)的階段服務這些客戶?
Are you positioned more into the later stages of drug development that is actually helping as capital funding is returning into the biotech? And maybe if you could, along those lines, talk a little bit about the biotech follow-on and capital raises. How is that flowing into your business?
你們是否更偏向藥物開發後期階段,這在生技資金回流時反而有幫助?另外,如果可以的話,也請沿著這個脈絡談談生技的後續融資與募資(capital raises)。這些資金如何流入並反映到你們的業務?
Padraig McDonnell - Chief Executive Officer, Director
Padraig McDonnell - Chief Executive Officer, Director
Yes. So I'll take the first one in general. I mean what's different? I think you see these numbers, and you see the 10 bps year-over-year operating margin expansion, 14% EPS growth. You're really seeing driven by a number of factors.
是的。我先回答第一個、整體性的問題。也就是:有什麼不同?我認為你看到這些數字——年對年營業利益率擴張 10 個基點、EPS 成長 14%——其實是由多個因素所驅動。
Replacement cycle continues to grow, but winning teams and being able to take market share in that environment. Innovations are really resonating Infinity Pro iQ LCMS and the upcoming launches at AMS will only drive that forward. And the share gains in this environment is really important, right? So that drives a lot of capacity as well. And I would say services remains a key differentiator for us. Our scale around services is super important.
汰換週期持續成長,但更重要的是有能打勝仗的團隊,並且能在那樣的環境中取得市占。創新確實引起共鳴,Infinity Pro iQ LCMS 以及即將在 AMS 的新品發布都會進一步推動。且在這種環境下的市占提升非常重要,對吧?因此也帶動了不少產能。我也會說,服務仍然是我們的關鍵差異化。我們在服務上的規模非常重要。
But when you look at our kind of operating system at Ignite, and I do want to take a minute on this one. It's a compounding effect that you see in the numbers this quarter, all three metrics above. And this is not a coincidence. And what happens when transformation is done right, when capabilities are not just piloted or incubated but deeply embedded in the system. That's what you're going to see compound over time.
但當你看我們在 Ignite 的營運系統——我也想在這點上花一點時間——你會在本季的數字中看到一種複利效應,三個指標都在上面。這不是巧合。當轉型做對了、當能力不只是試點或孵化,而是深度嵌入系統時,就會隨時間推移產生複利。
On the Pharma side, I think what you're seeing is really strong replacement cycle. You're seeing, of course, we have a tailwind with GLP-1s in those areas. And of course, the innovation is resonating. And you look at the long-term drivers in Pharma, you see distribution of supply chains, expansion of biologics, and of course, you see many other factors really helping.
在 Pharma 方面,我認為你看到的是非常強勁的汰換週期。當然,我們在那些領域也受惠於 GLP-1 的順風。而且創新正在引起共鳴。再看 Pharma 的長期驅動因素,你會看到供應鏈分散化、生物製劑(biologics)擴張,當然還有許多其他因素在提供助力。
But what I would say is that we're very much downstream in QA/QC. We're in development as well. So we're right in that sweet spot for reshoring replacement cycle and any capacity or supply chain resilience around. So feel really good about that.
但我想說的是,我們在 QA/QC 端其實非常偏下游。我們也在開發端。因此,我們正好處在回流(reshoring)替換週期,以及任何產能或供應鏈韌性需求的甜蜜點上。所以我們對此感覺非常好。
Of course, midsized biotech is a little bit challenged. As you see, but you see the number of deals that are happening from an investment point of view, and we expect that to improve as well. So overall, really, really positive.
當然,中型生技公司確實有點受挑戰,如你所見。但從投資角度來看,你也看到正在發生的交易數量,我們也預期這會改善。所以整體而言,真的非常、非常正面。
Operator
Operator
Dan Brennan, TD Cowen.
Dan Brennan,TD Cowen。
Daniel Brennan - Analyst
Daniel Brennan - Analyst
Congrats on the quarter. Maybe just on Diagnostics. I mean, super strong quarter. You highlighted the Omnis and some other things. I know you bumped the guide a bit, but it does imply a decel versus what you just printed.
恭喜本季表現。也許先談診斷業務(Diagnostics)。我是說,這一季非常強勁。你提到 Omnis 以及其他一些因素。我知道你把指引上調了一點,但這似乎暗示相較於你們剛公布的表現會出現減速。
Like was there anything unusual in this quarter on the Omnis that's not going to repeat? Or just kind of walk us through a little bit because it was so exceptional.
像是這一季在 Omnis 上是否有任何不尋常、未來不會重複的因素?或者能否帶我們稍微走一遍,因為表現實在太出色了。
Padraig McDonnell - Chief Executive Officer, Director
Padraig McDonnell - Chief Executive Officer, Director
Yeah, it was exceptional, Dan. Thanks for the question. We grew 11% in the quarter, well ahead of mid- to high-digit guidance on the side and very durable in that way.
是的,Dan,確實很出色。謝謝你的問題。我們本季成長 11%,明顯高於我們原先中到高個位數的指引,而且以這種方式來看非常具持續性。
But I'm going to bring in Simon to give more color on what he's seeing on the Omnis, et cetera.
不過我會請 Simon 進來,針對他在 Omnis 等方面看到的情況提供更多說明。
Simon May - Senior Vice President, President - Life Sciences and Diagnostics Markets Group
Simon May - Senior Vice President, President - Life Sciences and Diagnostics Markets Group
Thanks, Padraig. Simon again here. I think in Diagnostics, we've got two or three dynamics going on.
謝謝,Padraig。我是 Simon。我認為在診斷業務上,我們大概有兩到三個動態同時在發生。
First and foremost, we've identified this as one of our enterprise growth opportunities. And we've been focusing and investing there accordingly over the past 12, 18 months now. The Omnis family continues to ramp very well. We're very pleased with the trajectory that we're seeing there. across all regions. And we're also now starting to see similar growth in our assay attachments. It was a very pleasing quarter from that perspective because we saw double-digit growth in both instruments and assays.
首先也是最重要的,我們已將其識別為我們的企業級成長機會之一,並在過去 12 到 18 個月持續聚焦並相應投入。Omnis 產品家族持續爬坡得非常好,我們對目前看到的發展軌跡非常滿意,涵蓋所有地區。而且我們現在也開始在試劑(assay)搭載率上看到類似的成長。從這個角度看,這一季非常令人欣喜,因為我們看到儀器與試劑都出現雙位數成長。
We also continue to do very well in companion diagnostics. We've got great capabilities there. And we're seeing a lot of demand in modalities like antibody drug conjugates. So across the spectrum of our pathology and companion diagnostics business, I think we've got strong execution. And as Padraig mentioned, we've got durable market dynamics and a bit of a tailwind right now.
我們在伴隨式診斷(companion diagnostics)方面也持續表現非常好。我們在那裡具備很強的能力,並且在抗體藥物複合體(ADC)等治療模式上看到大量需求。因此,從我們的病理與伴隨式診斷業務全光譜來看,我認為我們執行力很強。如 Padraig 所提,我們也有具持續性的市場動能,且目前還有一些順風。
Daniel Brennan - Analyst
Daniel Brennan - Analyst
Perfect. And maybe as a follow-up. Padraig, you highlighted that slide in the deck, maybe it's slide 10 on the comps. So you're bumping the guide, but you are saying, hey, comps get harder, but we're up against that, and we feel good.
很好。那也許追問一下。Padraig,你提到簡報裡那張投影片,可能是第 10 頁,談到比較基期(comps)。所以你上調指引,但你也在說,嘿,基期會變得更具挑戰,但我們面對這點仍然有信心。
Can you just elaborate a little bit on within the guide? Because people stare at that? Like where do you think, ideally, you've left a little cushion because the comps are getting more difficult and Wall Street is intoxicated on beats. So just walk us through a little bit more on the guide and how we should think about the back half of the year.
你能否就指引內涵再多說一點?因為大家都盯著那個看。比如你理想上認為自己是否留了一點緩衝,因為比較基期變得更困難,而華爾街又很「沉迷」於超預期(beats)。所以請再帶我們更深入理解一下指引,以及我們該如何看待下半年。
Padraig McDonnell - Chief Executive Officer, Director
Padraig McDonnell - Chief Executive Officer, Director
I'm going to start off and hand it over to Adam. When you see the top-line strength, the confidence in Ignite drives incremental outlook for revenue growth and margin expansion and EPS. So 30 bps increase on the core growth side, 10 bps increase on the year-over-year margin expansion and EPS up $0.08. So I think the strong H2 results are really creating momentum out of it.
我先開頭,然後交給 Adam。當你看到營收端的強勁表現,對 Ignite 的信心會推動我們上調對營收成長、利潤率擴張與 EPS 的展望。因此,核心成長上調 30 個基點,年對年利潤率擴張上調 10 個基點,EPS 上調 0.08 美元。我認為下半年強勁的結果確實正在形成動能。
But Adam, do you want to give some more detail about what we're seeing and what we're taking into account?
不過 Adam,你要不要就我們看到的情況以及我們納入考量的因素提供更多細節?
Adam Elinoff - Chief Financial Officer, Senior Vice President
Adam Elinoff - Chief Financial Officer, Senior Vice President
Yeah. So thanks for the question. I would look at it a couple of ways.
好的。謝謝這個問題。我會用幾個角度來看。
So first of all, One, as you said, the compares get more challenging in H2, but you do have -- so you do have to look at that stacked growth view. But then when I think about it, the four kind of drivers that are going to -- that give me confidence going into it is, one, the execution excellence; two, you see we have market momentum.
首先,第一,如你所說,下半年的比較基期更具挑戰,但你確實需要用疊加成長(stacked growth)的視角來看。接著我在思考時,讓我對下半年有信心的四個驅動因素是:第一,卓越的執行力;第二,你看到我們有市場動能。
Three, the structural improvements that we've embedded through Ignite, they're in place and they're going to continue to compound. And then four is innovation, and you see that coming out shortly. And so those four are going to help kind of drive us through the second half of the year and what gives me confidence.
第三,我們透過 Ignite 內嵌的結構性改善已經到位,並且會持續累積效益。第四是創新,你很快就會看到相關成果推出。因此,這四項將幫助我們推動下半年,也就是我有信心的原因。
And then when I think about the guide, I'll just give you kind of how I think about kind of potential upsides and downsides for the full year to guide. Recall the last time we talked about it, there were kind of three -- the first being small and mid-cap, the second be Academia and Government and the third being a China stimulus.
再來談指引,我簡單說一下我如何看待全年指引可能的上行與下行。回想上次我們談到時,大概有三項:第一是小型與中型市值客戶;第二是學術與政府(Academia and Government);第三是中國刺激方案。
Well, China stimulus is now looking like the orders will happen toward the end of the year, but the revenue will come in the first part of next year. So we're taking that as an upside or downside off the table. And then where we would be left with is a small and mid-cap and what like Padraig talked about, is we're seeing all the green shoots there, and it just has to convert into revenue.
現在,中國刺激方案看起來訂單會在年底前後發生,但營收會在明年上半年入帳。因此,我們把這項作為上行或下行的因素先從桌面上拿掉。接下來剩下的就是小型與中型市值客戶;如 Padraig 所說,我們看到那裡出現各種「綠芽」(green shoots),接下來只需要轉化為營收。
Second is Academia and Government continued to stabilize. We saw it in the US. We see the right signs there. So there's -- we're cautiously optimistic as well there. And then you see the Middle East start to normalize, that's a potential source for upside as well as tariff refunds. So they're not embedded in our guide right now, but if we get a tariff refund, that can also help.
第二是學術與政府持續趨於穩定。我們在美國看到了,也看到那裡出現正確的跡象,所以我們也保持審慎樂觀。另外,你也看到中東開始正常化,這也是潛在的上行來源;此外還有關稅退稅(tariff refunds)。這些目前沒有納入我們的指引,但如果拿到關稅退稅,也會帶來幫助。
So overall, I just want to say, we're confident going in the second half of the year and the stack comps kind of tell the story.
總之,我只想說,我們對下半年有信心,而疊加比較基期(stack comps)也把故事講得很清楚。
Operator
Operator
Michael Ryskin, Bank of America. (Operator Instructions)
Michael Ryskin,美國銀行。(接線員指示)
Michael Ryskin - Analyst
Michael Ryskin - Analyst
Hopefully, you guys hear me. I want to follow up on China. I think you called out a 9% decline in the quarter. Maybe first half is in line.
希望你們聽得到我。我想追問中國。我記得你提到本季下滑 9%。也許上半年是符合預期。
But just anything specific to call out? You talked about slower funding delays in funding in China. Anything more specific than that? Or is it really that focused?
但有沒有任何更具體的因素可以補充?你談到中國資金撥付較慢、資金延遲。還有比這更具體的嗎?還是主要就是這個原因?
Padraig McDonnell - Chief Executive Officer, Director
Padraig McDonnell - Chief Executive Officer, Director
Yeah. Thanks, Michael. So we -- first of all, I think we see the China market as stable doing around $300 million [a quarter]. We saw larger-than-expected softness during to Lunar New Year, but H1 was flattish. We remain confident in our flattish guide. I think when you look at it, I think we are under-indexed to DX and Pharma and over-index to Applied as a company in China. But I think biotech is still as -- overall is still a small share of the overall China pharma market with nicely growing in high teens, which was a really bright spot for us, which shows the innovation that's happening in pharma et cetera, on it.
是的,謝謝,Michael。首先,我們認為中國市場是穩定的,每季大約在 3 億美元左右。我們在農曆新年期間看到比預期更大的疲軟,但上半年整體大致持平。我們對「大致持平」的指引仍有信心。我想如果你仔細看,我們公司在中國對診斷(DX)與製藥(Pharma)的曝險相對不足,而對應用(Applied)的曝險相對較高。但我認為生技在整體中國製藥市場中仍占比不大,且仍以十幾%的速度良好成長;這對我們而言是一個非常亮眼的點,顯示製藥等領域正在發生的創新。
And when you look at China overall, we're making investment in innovation. We're very highly committed to China. The speed of innovation there is really important. And of course, the stimulus will come in at the start of next year.
而從整體中國來看,我們正在投資創新。我們對中國的承諾非常高。那裡的創新速度非常重要。當然,刺激方案會在明年初開始反映。
And I think, overall, I think we continue to be optimistic. We expect mid-single to high single-digit growth for the long term. And the reasons why we feel that actually is not just because what we're seeing currently, but we have the largest installed base, the pace of innovation, everybody can read the details on that, and we're fully aligned with the China 15, five-year plan around AI, health care, green and sustainable developments and, of course, new regulations around PFAS.
整體而言,我認為我們仍保持樂觀。我們預期長期可達中個位數到高個位數成長。我們之所以這麼認為,不僅是基於目前看到的情況,還因為我們擁有最大的裝機基礎(installed base)、創新節奏——大家都可以自行閱讀相關細節——而且我們也與「中國十五五」五年規劃在 AI、醫療保健、綠色與永續發展等方向完全一致,當然也包括針對 PFAS 的新法規。
So overall, I would say, pretty muted in the quarter, but I would say very, very stable. And we're continuing to have a great team and really, really working with our customers there.
所以總體來說,本季表現相當溫和,但我會說非常、非常穩定。我們也持續擁有一支很強的團隊,並且真的非常努力地與當地客戶合作。
Michael Ryskin - Analyst
Michael Ryskin - Analyst
Okay. Okay. And maybe for my follow-up. I think on the last question, you kind of talked about US academic stabilizing, if I understood correctly, as one of the areas of upside for the year. If you could talk about A&G a little bit more globally, including China, just sort of what you're seeing there and what the assumptions for the rest of the year are?
好的,好的。那我追問一下。我想在上一個問題中,你提到如果我理解正確的話,美國學術端正在穩定,這可能是今年的上行來源之一。你能否更全球性地談談學術與政府(A&G),包括中國,說說你們看到的情況,以及對今年剩餘時間的假設是什麼?
Padraig McDonnell - Chief Executive Officer, Director
Padraig McDonnell - Chief Executive Officer, Director
Yeah. I mean China A&G is very soft in the quarter on tightened and delayed government spend leading to lower Academia stimulus. So I think that's what we're seeing. As I said, Americas was roughly flat. I think everywhere else is reasonably muted. In Europe, actually recovering on key markets, we're seeing reasonable business at Germany, UK, Spain. And then I think the Ukraine war impact is now budgeted in.
好的。我的意思是,中國的 A&G 本季非常疲弱,原因是政府支出收緊且延後,導致對學術端的刺激減少。我認為我們看到的就是這些。如我所說,美洲大致持平。我認為其他地區也相對偏溫和。歐洲其實在一些關鍵市場正在復甦,我們在德國、英國、西班牙看到還算不錯的業務表現。另外我認為烏克蘭戰爭的影響現在也已被納入預算考量。
And I think overall, I think just to put it into context, US is about 3% to 4% of sales. And there's a lot of uncertainty around multiyear grants and higher concentration of funding, but of course, you can see that we're working through that at the moment.
而且我認為整體來看,為了提供一些背景,美國約占銷售額的 3% 到 4%。而且圍繞多年期補助以及資金更高集中度存在很多不確定性,但當然,你可以看到我們目前正在處理這些問題。
Operator
Operator
(Operator Instructions) Dan Leonard, RBC.
(接線員指示)Dan Leonard,RBC。
Daniel Leonard - Analyst
Daniel Leonard - Analyst
I'll keep it to one. I have a question on spectroscopy. What is the replacement cycle look like there, especially on the back of a double-digit growth rate?
我只問一個。我有一個關於光譜(spectroscopy)業務的問題。那邊的汰換週期看起來如何,特別是在雙位數成長率之後?
So you have a new product launching, you expect -- it's going to drive a replacement cycle. Is that going to accelerate the growth rate further? And what would be the -- just kind of the framing around that?
你們有新產品要推出,你們預期——它會帶動一波汰換週期。這會不會進一步加速成長率?以及那個——就大概想請你們提供一下相關的框架說明?
Padraig McDonnell - Chief Executive Officer, Director
Padraig McDonnell - Chief Executive Officer, Director
Yeah, I'm going to bring in Mike Zhang here to talk about that spectroscopy business.
是的,我會請 Mike Zhang 進來談談那個光譜業務。
Mike Zhang - Senior Vice President, Agilent President, Applied Markets Group
Mike Zhang - Senior Vice President, Agilent President, Applied Markets Group
Yeah, Padraig. Again, thank you, Dan, for the great question. You've seen tremendous momentum. We're seeing the momentum from multiple fronts. First of all, obviously, the momentum in semiconductors and also data center. A lot of capacity build up. This is a global base. So very good excite.
好的,Padraig。再次感謝你,Dan,提出很好的問題。你已經看到非常強勁的動能。我們看到動能來自多個面向。首先,顯然是半導體以及資料中心的動能。大量的產能建置。這是全球性的基礎。所以非常令人振奮。
There's also, think about the very diverse upstream downstream applications, so a lot of [capacity]. But there's also a lot of pent-up demand because we know, in the last several years, the replacement cycle has kind of been muted. But we see now, because of the new demand, are we seeing acceleration. I think this is just the beginning. I think we had a lot of momentum moving ahead.
另外,也要想到非常多元的上游與下游應用,所以有很多[產能]。但同時也有很多被壓抑的需求,因為我們知道,過去幾年汰換週期某種程度上被抑制了。但我們現在看到,因為新的需求,我們是否看到加速。我認為這只是開始。我認為我們接下來會有很大的動能。
I think a lot of for us to expect. And we also really want to highlight, we're a very trusted partner by the customer. We are the absolute leader in the market. So -- and also now with the new innovation product coming out. So multiple fronts. We had exciting momentum, and I think this will continue on.
我認為我們還有很多值得期待的。而且我們也想強調,我們是客戶非常信賴的合作夥伴。我們是市場上的絕對領導者。所以——再加上現在新的創新產品即將推出。因此是多面向的推動。我們有令人振奮的動能,我認為這將會持續。
Operator
Operator
Luke Sergott, Barclays. (Operator Instructions)
Luke Sergott,Barclays。(接線員指示)
Luke Sergott - Analyst
Luke Sergott - Analyst
Great. Just a follow-up here on the margin commentary. Can you -- you guys had a really strong quarter like [Doc] was talking about on gross margin. You get the volume leverage. But then you're talking about some increased investment there, like pull forward on the ICP-MS launch.
很好。這裡針對毛利率評論追問一下。你們——你們這一季的表現非常強勁,正如[Doc]提到的,在毛利率方面。你們享有量的槓桿效益。但接著你們又談到一些增加投資,例如把 ICP-MS 的上市時程提前。
Like can you just talk about where -- how much is you're being pull forward on these investments and how that kind of shakes out? Just trying to think about from an exit rate margin opportunity and then as you kind of roll forward into a more normalized business environment through next year?
你們能否談談——這些投資提前的幅度有多大,以及最終會如何反映?我只是想從期末(exit rate)的毛利率機會來思考,然後當你們明年進入更正常化的營運環境時,這會如何演變?
Padraig McDonnell - Chief Executive Officer, Director
Padraig McDonnell - Chief Executive Officer, Director
Yeah. So let me take this one, Luke. So I think the pull forward in investment that you're talking about is really was a pull forward in the innovation and how we focused our investment. So it wasn't necessarily a pull forward in investment. The investments were always planned. As we talked about at the beginning of the year, we were going to take some of our margin improvement and best in innovation. So it really wasn't a timing issue around the investment itself.
好的,Luke,這題我來回答。我認為你所說的投資提前,實際上是創新方面的提前,以及我們如何聚焦投資。因此不一定是投資本身的提前。這些投資原本就有規劃。正如我們在年初所談,我們會把部分毛利率改善用於投資創新。所以就投資本身而言,並不是時點上的問題。
And then if you think about for the full year, we're guiding a full-year increase of about 85 bps at the midpoint. And once again, that incorporates several things. It's the structural improvements from Ignite, the volume leverage that we expect to get offset by inflation, and that's inflation kind of in the broad sense as well as some of the logistical Middle East costs in the AI and chip costs that we're seeing as well as then those growth investments.
然後如果你看全年,我們在中位數指引下,全年提升約 85 個基點。再一次,這包含幾個因素:Ignite 帶來的結構性改善、我們預期取得的量的槓桿效益,並被通膨所抵銷——這裡的通膨是廣義的通膨,也包括我們看到的一些物流方面的中東成本,以及 AI 與晶片成本,另外還有那些成長型投資。
And so to your question, it was always incorporated into our initial guide, and we're raising our margin guide for the full year, up 10 bps at the midpoint.
所以回到你的問題,這些原本就已納入我們最初的指引之中,而我們把全年毛利率指引在中位數上調了 10 個基點。
Operator
Operator
Catherine Schulte, Baird.
Catherine Schulte,Baird。
Catherine Schulte - Analyst
Catherine Schulte - Analyst
On Food, just given that was the one part of the guide that came down. You talked about delays in China and India. Can you just unpack a bit what you're seeing there and how you expect that to play out going forward?
關於食品(Food),因為那是指引中唯一下修的部分。你們提到中國和印度的延遲。你們能否再多拆解一下你們在那裡看到的情況,以及你們預期未來會如何發展?
Padraig McDonnell - Chief Executive Officer, Director
Padraig McDonnell - Chief Executive Officer, Director
Yeah. So I think -- thanks for the question. The Food market business declined minus 3% in Q2, and that was against the mid-single-digit guide, really around delayed government spending in Asia was the primary driver of the shortfall versus expectations. American Europe grew together in high single digits during the quarter. And for FY26 to reduce guidance from flat to low single to negative low single digits.
好的。我想——謝謝你的問題。食品市場業務在第二季下滑 -3%,而我們原本的指引是中個位數成長,主要落差來自亞洲政府支出延後,這是低於預期的主要原因。美洲與歐洲在本季合計成長高個位數。至於 FY26,我們把指引從持平到低個位數,調整為負的低個位數。
We're set up, I think, in FY27 to see the China stimulus. But the China stimulus from last year really set up a tough comp for us in FY26 and slower government funding. And of course, pressure from the Middle East conflict on food shipments and testing in Asia is an incremental challenge.
我認為我們在 FY27 的布局,將可受惠於中國刺激政策。但去年的中國刺激政策,讓 FY26 的比較基期變得很硬,再加上政府資金放緩。當然,中東衝突對食品運輸與亞洲檢測造成的壓力,也是額外的挑戰。
But I would say, overall, what you're seeing driving this market for us is that we're ever-changing food safety regulations. They're not going to change. You're going to see customer demand continue for healthier, sustainable alternative foods, and of course, contract lapsing increased sample volumes. So I think that's where we're right in our sweet spot with verified workflows.
但我會說,整體而言,你看到推動我們這個市場的因素是:食品安全法規持續變動——而且不會停止;你會看到客戶對更健康、可持續的替代食品需求持續;當然,合約到期也帶來樣本量增加。所以我認為這正是我們以經驗證的工作流程(verified workflows)所擅長的領域。
Emerging PFAS in food is going to continue. It's actually a really strong growth area over time. and of course, protection of core food safety and quality testing. So overall, a challenging quarter, but I think the long term looks very strong.
食品中的新興 PFAS 將會持續存在。長期來看,這其實是非常強勁的成長領域;當然也包括核心食品安全與品質檢測的防護。因此整體來說,這是一個具挑戰的季度,但我認為長期前景非常強勁。
Operator
Operator
Casey Woodring, JPMorgan.
Casey Woodring,JPMorgan。
Casey Woodring - Analyst
Casey Woodring - Analyst
Congrats on the quarter. Yeah, I'll just ask my two upfront. First is just would be curious to hear how much that forensic TSA one-timer, you called out was in the quarter? And was that baked into the guide?
恭喜這一季的表現。好的,我就先問我這兩個。第一個是,我想了解你們提到的法證(forensic)TSA 一次性(one-timer)在本季的金額大概是多少?以及那是否已經納入指引?
And then second, on chemical within CAM, not to beat a dead horse, but would also be curious to hear if the strong CapEx in Chemical is limited to the US or if that's more broad-based in Europe and Asia as well? And maybe just unpack what you're seeing ex-US and that business and what your Chemical exposure is ex-US.
第二個,在 CAM 裡的化學(chemical)方面,不想老調重彈,但也想了解化學領域強勁的資本支出(CapEx)是否僅限於美國,還是歐洲與亞洲也同樣廣泛?也請你們拆解一下你們在美國以外看到的情況,以及你們在美國以外的化學曝險(exposure)如何。
Padraig McDonnell - Chief Executive Officer, Director
Padraig McDonnell - Chief Executive Officer, Director
Yeah. So first of all, I'm going to bring Mike in to talk about the TSA business because it's something that is -- we're really, really excited about, and I'll come back and I'll talk about CAM.
好的。首先,我會請 Mike 來談 TSA 業務,因為這是——我們真的、真的很興奮的事情;之後我再回來談 CAM。
Mike Zhang - Senior Vice President, Agilent President, Applied Markets Group
Mike Zhang - Senior Vice President, Agilent President, Applied Markets Group
Yeah, definitely. TSA, the this solution is highly differentiated. And it provides [unprecedented] positions, but also a efficient throughput. We have been successfully working with TSA and we have deployed the first contractor ahead of the FIFA Cup 2026.
好的,當然。TSA,這個解決方案具有高度差異化。它提供[前所未有]的能力,同時也有高效率的處理量(throughput)。我們一直與 TSA 成功合作,並且已在 2026 年 FIFA 世界盃之前部署了第一個合約。
The successful deployed the first contract and a continuous collaboration really position us in a very strong position to future tenders. So overall, I think this is exciting new opportunity for us.
成功部署第一個合約,以及持續的合作,讓我們在未來標案中處於非常有利的位置。整體而言,我認為這對我們來說是令人振奮的新機會。
Padraig McDonnell - Chief Executive Officer, Director
Padraig McDonnell - Chief Executive Officer, Director
Yeah. And we called out a $9 million TSA win last quarter with Forensics. We recognized $5 million of that this quarter. And we're really well positioned to continue to secure larger aviation security tenders as we go forward.
是的。我們在上一季提到法證業務拿下了一筆 900 萬美元的 TSA 訂單。我們在本季認列了其中的 500 萬美元。而且我們在未來持續爭取更大型的航空安檢標案方面,具備非常好的位置。
And it's important to also kind of continue -- that's going to have continued tech refresh in it as well. When you go back to CAM as well, it's not one region. We're seeing it across all regions. So I think we feel really strong about our funnels as well geographically, too.
同時也很重要的是要持續——這裡面也會有持續的技術更新(tech refresh)。再回到 CAM,也不是只有單一地區。我們在所有地區都看到了。因此我認為我們對於我們的商機漏斗(funnels)在地理分布上也感到非常有信心。
Operator
Operator
This is all the time we have for questions today. I will turn the call back over to Mr. Tejas for closing remarks.
今天的提問時間就到這裡。我會把電話會議交回給 Tejas 先生做結語。
Tejas Savant - Vice President of Investor Relations
Tejas Savant - Vice President of Investor Relations
Thank you, everyone, for joining us. We look forward to speaking with many of you in the weeks ahead.
謝謝各位的參與。我們期待在接下來幾週與各位中的許多人交流。
Operator
Operator
This concludes today's call. Thank you for attending. You may now disconnect.
今天的電話會議到此結束。感謝各位出席。您現在可以掛線。